GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Research & Development

CERO (CERo Therapeutics Holdings) Research & Development : $5.51 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. CERo Therapeutics Holdings's Research & Development for the three months ended in Dec. 2024 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was $5.51 Mil.

CERo Therapeutics Holdings Research & Development Historical Data

The historical data trend for CERo Therapeutics Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Research & Development Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Research & Development
9.14 9.85 5.29 -

CERo Therapeutics Holdings Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.02 - 2.71 1.77 -

CERo Therapeutics Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CERo Therapeutics Holdings  (NAS:CERO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CERo Therapeutics Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Research & Development
Comparable Companies
BZYR AZTR CPMV KTTA KLTO AIMI VRAX AEON ADIL ALZN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, South San Francisco, San Francisco, CA, USA, 94080
Website
https://www.cero.bio
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.